University of Colorado, Denver
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Colorado, Denver sits in the top decile of US sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count).
University of Colorado, Denver: 1,283 sponsored US clinical trials, 265 recruiting.
University of Colorado, Denver sponsors 1,283 registered US clinical trials on ClinicalTrials.gov, 265 of them currently recruiting, and 830 completed. 121 of these trials are in Phase 3-4 (later-stage) and 245 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 23 trials.
Top-decile sponsor footprint
University of Colorado, Denver ranks in the top decile of sponsors by registered trial count (#21 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
830 of 908 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,283 total, page 23 of 26
School Located Adolescent Vaccination Study
NCT01719679
Acupuncture for Fatigue in Parkinson's Disease
NCT01360229
Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users
NCT01161485
Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
NCT01186003
Effectiveness and Costs of Remote Monitoring for Clinical Trials
NCT01151995
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
NCT01201850
Reproductive Hormonal Alterations in Obesity
NCT01457703
Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis
NCT01101386
Population Versus Practice-based Interventions to Increase Immunizations
NCT01296906
Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents
NCT01102374
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
NCT01153100
Muscle Treatment for Management of Pain & Disability in Tension-type Headache
NCT01244555
Estrogen and Serotonin on Changing Brain Chemistry
NCT01208324
Trial to Optimize Mineral Outcomes in Dialysis Patients
NCT01100723
Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy
NCT01209507
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
NCT01097395
Association Between the Menstrual Cycle and Weight Loss
NCT01119976
Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine
NCT01192828
Window of Opportunity Study Targeting the Inflammatory Milieu
NCT01881048
Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes
NCT01209312
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
NCT02353468
Self-Management and Resourceful Transition of Type 2 Diabetes With Stage 3 Kidney Disease
NCT01067963
OSI-906 and Irinotecan in Patients With Advanced Cancer
NCT01016860
Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians_Matlock
NCT01190488
Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial
NCT01145391
The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
NCT01112670
Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
NCT01019486
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02353572
Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections
NCT00996112
Energy Expenditure and Weight Loss Maintenance
NCT03422380
A Pragmatic Trial of the Effect of a Mailed Patient Flyer About Prostate Specific Antigen (PSA) Testing Prior to an Annual Exam
NCT01516801
Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
NCT00948194
Lung Cancer Mutation Consortium Protocol
NCT01014286
Treatment of Critical Illness Polyneuromyopathy
NCT01058421
Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes
NCT00978796
Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
NCT00936377
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
NCT00985738
Collaborative Efforts to Increase Flu Vaccination
NCT01403649
Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians
NCT01099943
Assessment of Spinal Stability
NCT01060358
Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
NCT00938405
Effect of Antacids on the Pharmacokinetics of Raltegravir
NCT00944307
Medication Management and Culture of Safety
NCT01247454
Family Program for Weight Gain Prevention
NCT00989170
Autoimmune Thyroid Disease Genetic Study
NCT00958113
Antioxidant Replacement Therapy in Patients With Alcohol Abuse
NCT00936000
The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients
NCT02634658
A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders
NCT01765309
Outreach for Diabetes Cure
NCT01384045
Bupropion for ADHD in Adolescents With Substance Use Disorder
NCT00936299
What is open in the University of Colorado, Denver pipeline
265 recruiting of 1,283 indexed (21% open); 830 completed (65%).
Phase mix: 121 late (III/IV) vs 245 early (I/II) (early-phase heavy).
Top condition: Obesity (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Colorado, Denver: open-pipeline peers nationwide
Peers matched on 1,283 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
University of Colorado, Denver sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,283 trials (± recruiting share)
- AstraZeneca · 1,285 trials · 12% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Cedars-Sinai Medical Center · 21% recruiting · 339 trials
- Craig Hospital · 21% recruiting · 29 trials
- W.L.Gore & Associates · 21% recruiting · 53 trials
- Georgia Institute of Technology · 21% recruiting · 24 trials
Related
What to do with this University of Colorado, Denver page
1,283 registered trials is a research-attention snapshot, not an endorsement of University of Colorado, Denver or any single study.
- 265 of University of Colorado, Denver's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Colorado, Denver studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Colorado, Denver pipeline card: 1,283 registered trials from official public datasets.Report a data error.